Department of Surgery, City of Hope National Medical Center, Duarte, CA, USA.
Department of Surgery, City of Hope National Medical Center, Duarte, CA, USA; Center for Gene Therapy, Department of Hematology and Hematopoietic Cell Transplantation, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA; Gene Editing and Viral Vector Core, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, USA.
Curr Opin Immunol. 2018 Apr;51:83-90. doi: 10.1016/j.coi.2018.03.008. Epub 2018 Mar 16.
Initially, direct oncolysis was thought to be the sole mechanism through which oncolytic viruses (OVs) exert their anti-tumor effect, and the immune system was perceived as the major obstacle in oncolytic virotherapy. Over the last decade, there has been a lot of debate on whether the immune system is a friend or foe of OVs. However, we are now at a stage where the initial thinking has been reversed as a result of compelling evidence that the immune system plays a critical role in the success of oncolytic virotherapy. In this review we discuss the importance of the involvement of innate and adaptive immunity for therapeutic efficacy of OVs, and the rational combination of OVs with other immunotherapies for further enhancement of overall therapeutic outcome.
最初，人们认为溶瘤病毒（OVs）发挥抗肿瘤作用的唯一机制是直接溶瘤，而免疫系统被认为是溶瘤病毒治疗的主要障碍。在过去的十年中，关于免疫系统是溶瘤病毒的朋友还是敌人一直存在很多争议。然而，由于有力的证据表明免疫系统在溶瘤病毒治疗的成功中起着关键作用，我们现在正处于最初的想法被颠覆的阶段。在这篇综述中，我们讨论了先天免疫和适应性免疫对 OVs 治疗效果的重要性，以及 OVs 与其他免疫疗法的合理联合应用，以进一步提高整体治疗效果。
